Literature DB >> 33658016

Site of relapse of ductal adenocarcinoma of the pancreas affects survival after multimodal therapy.

S A Safi1, N Lehwald-Tywuschik1, A Rehders1, G Fluegen1, L Haeberle2, V Keitel3, W T Knoefel4.   

Abstract

BACKGROUND: Ductal adenocarcinoma of the pancreas (PDAC) remains one of the most lethal malignancies. To date, no guidelines exists for isolated resectable metachronous disease. It is still unknown, which patients may benefit from relapse surgery. The aim of our study was to compare disease free survival (DFS) and post relapse survival (PRS) in patients with isolated local recurrence, metachronous hepatic or pulmonary metastases.
METHODS: Patients with isolated resectable local recurrence, metachronous hepatic or pulmonary metastases were included for survival analyses. PRS of surgically treated patients (local (n = 11), hepatic (n = 6) and pulmonary metastases (n = 9)) was compared to conservatively treated patients (local (n = 17), hepatic (n = 37) and pulmonary metastases (n = 8)).
RESULTS: Resected PDAC patients suffering from isolated metachronous hepatic metastases initially had a higher T-stage and venous invasion (V1) compared to the other patients. DFS in the metachronous pulmonary metastases group was longer compared to DFS of the hepatic metastases and local recurrence groups. Surgical resection significantly improved PRS in patients with local recurrence and pulmonary metastases, when compared to patients receiving chemotherapy alone. Very-long term survivors (> 5 years) were detected following secondary resection of local recurrence and 45% of these patients were still alive at the end of our study period.
CONCLUSION: Although DFS in PDAC patients suffering from isolated local recurrence was dismal and comparable to that of patients with isolated hepatic metastases, very-long term survivors were present only in this group. These results indicate that a surgical approach for isolated local recurrence, if anatomically possible, should be considered.

Entities:  

Keywords:  Ductal adenocarcinoma of the pancreas; Hepatic metastases; Local recurrence; Oligometastatic; PDAC; Pulmonary metastases; Survival outcome

Mesh:

Year:  2021        PMID: 33658016      PMCID: PMC7931536          DOI: 10.1186/s12893-021-01082-w

Source DB:  PubMed          Journal:  BMC Surg        ISSN: 1471-2482            Impact factor:   2.102


  4 in total

1.  Successful outcome after resection of pancreatic cancer with a solitary hepatic metastasis.

Authors:  Kazuaki Shimada; Tomoo Kosuge; Junji Yamamoto; Susumu Yamasaki; Michiie Sakamoto
Journal:  Hepatogastroenterology       Date:  2004 Mar-Apr

2.  Pancreatic adenocarcinoma.

Authors:  David P Ryan; Theodore S Hong; Nabeel Bardeesy
Journal:  N Engl J Med       Date:  2014-11-27       Impact factor: 91.245

3.  Cancer statistics, 2020.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2020-01-08       Impact factor: 508.702

4.  Pulmonary adenocarcinoma occurring 5 years after resection of a primary pancreatic adenocarcinoma: a relevant differential diagnosis.

Authors:  R F Falkenstern-Ge; M Wohlleber; M Kimmich; K Huettl; G Friedel; G Ott; M Kohlhäufl
Journal:  Case Rep Oncol Med       Date:  2014-02-23
  4 in total
  1 in total

1.  Genetic Alterations Predict Long-Term Survival in Ductal Adenocarcinoma of the Pancreatic Head.

Authors:  Sami-Alexander Safi; Lena Haeberle; Wolfgang Goering; Verena Keitel; Georg Fluegen; Nikolas Stoecklein; Alexander Rehders; Wolfram Trudo Knoefel; Irene Esposito
Journal:  Cancers (Basel)       Date:  2022-02-08       Impact factor: 6.639

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.